Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Raclopride
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Raclopride

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed6 referencesApproximately 4 min read

A substituted benzamide that has antipsychotic properties.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (889 words), 6 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see receptors, dopamine D2) antagonist.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: FLA-870; FLA870; FLA 870; FLB-472; FLB472; FLB 472; Raclopride C11; C11, Raclopride.

Where it fits in the MeSH classification

Broader topics
Benzamides; Chlorobenzoates

Related concepts

  • Receptors
  • Dopamine

Research landscape

PubMed indexes 1,830 records tagged with the MeSH heading “Raclopride” (counts retrieved 2026-10-31). 105 of them (5.7%) were published from 2020 onward, and the busiest period so far is 2000-2009 with 685 records.

Reviews account for 29 records (1.6%) and meta-analyses for 3. Randomized controlled trials number 45 (2.5%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 605 records; 2000-2009: 685 records; 2010-2019: 435 records; 2020 onward: 105 records605through 19996852000-20094352010-20191052020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999605
2000-2009685
2010-2019435
2020 onward105
Share of records by publication typeReviews: 1.6 percent; Meta-analyses: 0.2 percent; Randomized controlled trials: 2.5 percentReviews1.6% (29)Meta-analyses0.2% (3)Randomized controlled trials2.5% (45)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 1,830 PubMed records
TypeRecordsShare
Reviews291.6%
Meta-analyses30.2%
Randomized controlled trials452.5%

Method: PubMed query "Raclopride"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Neurophysiological effects of sleep deprivation in healthy adults, a pilot study
Klumpers UM, Veltman DJ, van Tol MJ, Kloet RW, Boellaard R, Lammertsma AA, et al.
2015Research article
Design not recorded in structured metadata
36cc by
PMID 25608023 · DOI · PMC4301911
Time-dependent assessment of stimulus-evoked regional dopamine release
Lippert RN, Cremer AL, Edwin Thanarajah S, Korn C, Jahans-Price T, Burgeno LM, et al.
2019Research article
Design not recorded in structured metadata
34cc by
PMID 30659189 · DOI · PMC6338792
Evidence of dopaminergic processing of executive inhibition
Badgaiyan RD, Wack D
2011Research article
Design not recorded in structured metadata
26cc0
PMID 22162756 · DOI · PMC3230601
Brain connectivity changes to fast versus slow dopamine increases
Manza P, Tomasi D, Vines L, Sotelo D, Yonga MV, Wang GJ, et al.
2024Randomized controlled trial
Design not recorded in structured metadata
11cc by
PMID 38326458 · DOI · PMC11039764

Neurophysiological effects of sleep deprivation in healthy adults, a pilot study [1]

Research article Klumpers UM, Veltman DJ, van Tol MJ, Kloet RW, Boellaard R, Lammertsma AA, et al. · · 2015 · cited 36 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Total sleep deprivation (TSD) may induce fatigue, neurocognitive slowing and mood changes, which are partly compensated by stress regulating brain systems, resulting in altered dopamine and cortisol levels in order to stay awake if needed.
Closing excerpt
The blunted HPA-axis response together with altered [11C]raclopride binding in the basal ganglia indicate that sustained wakefulness requires involvement of additional adaptive biological systems.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (257 words)

Total sleep deprivation (TSD) may induce fatigue, neurocognitive slowing and mood changes, which are partly compensated by stress regulating brain systems, resulting in altered dopamine and cortisol levels in order to stay awake if needed. These systems, however, have never been studied in concert. At baseline, after a regular night of sleep, and the next morning after TSD, 12 healthy subjects performed a semantic affective classification functional magnetic resonance imaging (fMRI) task, followed by a [11C]raclopride positron emission tomography (PET) scan. Saliva cortisol levels were acquired at 7 time points during both days. Affective symptoms were measured using Beck Depression Inventory (BDI), Spielberger State Trait Anxiety Index (STAI) and visual analogue scales. After TSD, perceived energy levels, concentration, and speed of thought decreased significantly, whereas mood did not. During fMRI, response speed decreased for neutral words and positive targets, and accuracy decreased trendwise for neutral words and for positive targets with a negative distracter. Following TSD, processing of positive words was associated with increased left dorsolateral prefrontal activation. Processing of emotional words in general was associated with increased insular activity, whereas contrasting positive vs. negative words showed subthreshold increased activation in the (para)hippocampal area. Cortisol secretion was significantly lower after TSD. Decreased voxel-by-voxel [11C]raclopride binding potential (BPND) was observed in left caudate. TSD induces widespread cognitive, neurophysiologic and endocrine changes in healthy adults, characterized by reduced cognitive functioning, despite increased regional brain activity. The blunted HPA-axis response together with altered [11C]raclopride binding in the basal ganglia indicate that sustained wakefulness requires involvement of additional adaptive biological systems.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25608023 · DOI · PMC4301911

Time-dependent assessment of stimulus-evoked regional dopamine release [2]

Research article Lippert RN, Cremer AL, Edwin Thanarajah S, Korn C, Jahans-Price T, Burgeno LM, et al. · · 2019 · cited 34 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
To date, the spatiotemporal release of specific neurotransmitters at physiological levels in the human brain cannot be detected.
Closing excerpt
This method enables time-dependent regional monitoring of stimulus-evoked dopamine release at physiological levels.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (144 words)

To date, the spatiotemporal release of specific neurotransmitters at physiological levels in the human brain cannot be detected. Here, we present a method that relates minute-by-minute fluctuations of the positron emission tomography (PET) radioligand [11C]raclopride directly to subsecond dopamine release events. We show theoretically that synaptic dopamine release induces low frequency temporal variations of extrasynaptic extracellular dopamine levels, at time scales of one minute, that can evoke detectable temporal variations in the [11C]raclopride signal. Hence, dopaminergic activity can be monitored via temporal fluctuations in the [11C]raclopride PET signal. We validate this theory using fast-scan cyclic voltammetry and [11C]raclopride PET in mice during chemogenetic activation of dopaminergic neurons. We then apply the method to data from human subjects given a palatable milkshake and discover immediate and-for the first time-delayed food-induced dopamine release. This method enables time-dependent regional monitoring of stimulus-evoked dopamine release at physiological levels.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30659189 · DOI · PMC6338792

Evidence of dopaminergic processing of executive inhibition [3]

Research article Badgaiyan RD, Wack D · · 2011 · cited 26 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Inhibition of unwanted response is an important function of the executive system.
Closing excerpt
The results provide evidence of dopaminergic processing of executive inhibition and demonstrate that neurochemical changes associated with cognitive processing can be detected and mapped in a single scan session using dynamic molecular imaging.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (255 words)

Inhibition of unwanted response is an important function of the executive system. Since the inhibitory system is impaired in patients with dysregulated dopamine system, we examined dopamine neurotransmission in the human brain during processing of a task of executive inhibition. The experiment used a recently developed dynamic molecular imaging technique to detect and map dopamine released during performance of a modified Eriksen's flanker task. In this study, young healthy volunteers received an intravenous injection of a dopamine receptor ligand ((11)C-raclopride) after they were positioned in the PET camera. After the injection, volunteers performed the flanker task under Congruent and Incongruent conditions in a single scan session. They were required to inhibit competing options to select an appropriate response in the Incongruent but not in the Congruent condition. The PET data were dynamically acquired during the experiment and analyzed using two variants of the simplified reference region model. The analysis included estimation of a number of receptor kinetic parameters before and after initiation of the Incongruent condition. We found increase in the rate of ligand displacement (from receptor sites) and decrease in the ligand binding potential in the Incongruent condition, suggesting dopamine release during task performance. These changes were observed in small areas of the putamen and caudate bilaterally but were most significant on the dorsal aspect of the body of left caudate. The results provide evidence of dopaminergic processing of executive inhibition and demonstrate that neurochemical changes associated with cognitive processing can be detected and mapped in a single scan session using dynamic molecular imaging.

Abstract reproduced from the open-access article under the recorded cc0 licence; © the authors. PMID 22162756 · DOI · PMC3230601

Brain connectivity changes to fast versus slow dopamine increases [4]

Randomized controlled trial Manza P, Tomasi D, Vines L, Sotelo D, Yonga MV, Wang GJ, et al. · · 2024 · cited 11 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The rewarding effects of stimulant drugs such as methylphenidate (MP) depend crucially on how fast they raise dopamine in the brain.
Closing excerpt
Fast dopamine increases are uniquely associated with connectivity patterns that have relevance for the subjective experience of drug reward.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (233 words)

The rewarding effects of stimulant drugs such as methylphenidate (MP) depend crucially on how fast they raise dopamine in the brain. Yet how the rate of drug-induced dopamine increases impacts brain network communication remains unresolved. We manipulated route of MP administration to generate fast versus slow dopamine increases. We hypothesized that fast versus slow dopamine increases would result in a differential pattern of global brain connectivity (GBC) in association with regional levels of dopamine D1 receptors, which are critical for drug reward. Twenty healthy adults received MP intravenously (0.5 mg/kg; fast dopamine increases) and orally (60 mg; slow dopamine increases) during simultaneous [11C]raclopride PET-fMRI scans (double-blind, placebo-controlled). We tested how GBC was temporally associated with slow and fast dopamine increases on a minute-to-minute basis. Connectivity patterns were strikingly different for slow versus fast dopamine increases, and whole-brain spatial patterns were negatively correlated with one another (rho = -0.54, pspin slow" associations in dorsal prefrontal cortex, insula, posterior thalamus and brainstem, caudate and precuneus; and "slow>fast" associations in ventral striatum, orbitofrontal cortex, and frontopolar cortex (pFDR slow" GBC patterns showed significant spatial correspondence with D1 receptor availability (estimated via normative maps of [11C]SCH23390 binding; rho = 0.22, pspin (19) = -0.68, pbonferroni = 0.015). Different routes of MP administration produce divergent patterns of brain connectivity. Fast dopamine increases are uniquely associated with connectivity patterns that have relevance for the subjective experience of drug reward.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38326458 · DOI · PMC11039764

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism [5]
    Ginovart N · Mol Imaging Biol · 2005 · cited 58 times (Europe PMC)
  • Research article Optimisation of [11C]Raclopride production using a Synthra GPextent system [6]
    Perkins G, Sheth R, Greguric I, Pascali G · Curr Radiopharm · 2014 · cited 3 times (Europe PMC)

References

  1. Klumpers UM, Veltman DJ, van Tol MJ, Kloet RW, Boellaard R, Lammertsma AA, et al.. Neurophysiological effects of sleep deprivation in healthy adults, a pilot study. . 2015. PMID 25608023 · DOI · PMC4301911
  2. Lippert RN, Cremer AL, Edwin Thanarajah S, Korn C, Jahans-Price T, Burgeno LM, et al.. Time-dependent assessment of stimulus-evoked regional dopamine release. . 2019. PMID 30659189 · DOI · PMC6338792
  3. Badgaiyan RD, Wack D. Evidence of dopaminergic processing of executive inhibition. . 2011. PMID 22162756 · DOI · PMC3230601
  4. Manza P, Tomasi D, Vines L, Sotelo D, Yonga MV, Wang GJ, et al.. Brain connectivity changes to fast versus slow dopamine increases. . 2024. PMID 38326458 · DOI · PMC11039764
  5. Ginovart N. Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol Imaging Biol. 2005. PMID 15912275 · DOI
  6. Perkins G, Sheth R, Greguric I, Pascali G. Optimisation of [11C]Raclopride production using a Synthra GPextent system. Curr Radiopharm. 2014. PMID 25335809 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Imatinib MesylateDrugs and Chemicals
  • ProcarbazineDrugs and Chemicals
  • SulpirideDrugs and Chemicals
  • SimvastatinDrugs and Chemicals
  • SorafenibDrugs and Chemicals
  • 2-AcetylaminofluoreneDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

1,830
PubMed records on this heading
6%
published since 2020
29
review articles
45
randomized trials
6
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Imatinib MesylateDrugs and Chemicals
  • ProcarbazineDrugs and Chemicals
  • SulpirideDrugs and Chemicals
  • SimvastatinDrugs and Chemicals
  • SorafenibDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support